Is it time for geriatricians to get on board with lecanemab? Jason Karlawish and Ken Covinsky
GeriPal
DECEMBER 15, 2022
In an article in the NEJM (a published article this time, wonder of wonders!) So we have community volunteers who often they have a background in writing or background in healthcare, certainly an interest in interviewing and an interest in writing. But wait, there’s a shiny new anti-amyloid drug, lecanemab! (No Oh my gosh.
Let's personalize your content